Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide)
Brand Names: Cold Flu
Methodology & AI Transparency ⓘ
Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Cold Flu (registered by HyVee Inc, RxNorm 2604561), this over-the-counter branded formulation contains Acetaminophen, Dextromethorphan Hydrobromide within the Antihistamine therapeutic class.
- 2 Real-world patient consensus: Branded antihistamine presentation of Acetaminophen, Dextromethorphan Hydrobromide (HyVee Inc); generic reference RxCUI 2604561.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $9.90 cash mean against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) tolerability events: headache (8.5%), cough (5.5%), application-site irritation (4.6%).
Ask our AI Specialists anything about Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide)
Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Cold Flu (registered by HyVee Inc, RxNorm 2604561), this over-the-counter branded formulation contains Acetaminophen, Dextromethorphan Hydrobromide within the Antihistamine therapeutic class. Per 2026-03-20 DailyMed labeling (42507-532, 42507-598), clinical use centers on Kit; 325 mg/15mL / 10 mg/15mL Solution: Uses ; temporarily relieves common cold/flu symptoms: ; cough due to minor throat and bronchial irritation ; sore throat.
At the receptor and enzymatic level, Cold Flu delivers Acetaminophen, Dextromethorphan Hydrobromide to execute antihistamine modulation with class-characteristic hepatorenal disposition. Specific to the Cold Flu commercial product (NDC 42507-532, 42507-598, RxCUI 2604561), tablet/vehicle compounding registered by HyVee Inc standardizes delivery across Kit; 325 mg/15mL / 10 mg/15mL Solution, contrasting $9.90 discount cash access against $34.50 walk-in retail pricing.
Systemic exposure to Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) reflects Approximately 49% to 61% enteral uptake across labeled Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) strengths absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar cold flu (acetaminophen, dextromethorphan hydrobromide) conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 3–12 hour t½ intervals for Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) half-life window (maximum serum exposure occurs 2–4 hours after cold flu (acetaminophen, dextromethorphan hydrobromide) dosing response profile).
Dosing protocols (Kit or 325 mg/15mL / 10 mg/15mL Solution) balance efficacy (92.00% patient satisfaction across 13 logs) against headache (8.5% of reports), nausea (7.5% of reports), dizziness (6.5% of reports), with strict avoidance in confirmed ige-mediated allergy or cutaneous reaction to cold flu (acetaminophen, dextromethorphan hydrobromide) (acetaminophen, dextromethorphan hydrobromide) components; uncompensated hepatic or renal insufficiency incompatible with cold flu (acetaminophen, dextromethorphan hydrobromide) (kit) clearance.
Reconcile eGFR-adjusted medications before escalating Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) (Acetaminophen, Dextromethorphan Hydrobromide) components
- Uncompensated hepatic or renal insufficiency incompatible with Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) (Kit) clearance
Logged Side-Effect Incidence (13 Reports)
Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Check Your Medicine Cabinet: HAIFA SMOKED FISH Recalls Cold Smoked Sprats Due to Potential Health Risk HAIFA SMOKED FISH of QUEENS NY is recalling approximately 560 lbs. of Cold Smoked Sprats, due to potential contamination with Clostridium botulinum, a bacterium which can cause life-threatening illness. Consumers are warned not to use the product even if it do FDA Drug Recalls • 2026-10-27 • FDA Recall | Multi-cohort | 95/100 | PMID FDA_RECALLS-1160800238 ↗ |
| New Insights on Benefits and safety of intranasal bencycloquidium bromide in nasal symptoms of: What a 480-Participant Study Found BCQB nasal spray is effective and safe for treating rhinorrhea, nasal congestion and sneezing associated with common cold. QJM : monthly journal of the Association of Physicians • 2026-06-01 • Phase III Randomized Trial | N = 480 | 93/100 | PMID 41476148 ↗ |
| New Insights on Benefits and safety of AP-Bio®(KalmCold®) in participants with uncomplicated: What a 331-Participant Study Found Participants in both the AP-Bio® dose groups showed positive tendency towards resolution of URTI symptoms when compared with placebo on Day-3 but not on Day-5 and Day-7. Complementary therapies in medicine • 2023-05-15 • Phase III Randomized Trial | N = 331 | 93/100 | PMID 36842634 ↗ |
| Managing Cold agglutinin disease: Can Sutimlimab Make a Real Difference? (What New Research Reveals) These data demonstrate that sutimlimab has potential to be an important advancement in the treatment of CAD. Blood • 2022-09-01 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 35687757 ↗ |
Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0194/unit (~$0.58/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $9.90 / mo | View logs ↓ |
Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) RxNorm Concept ID | 2604561 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0194 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) (antihistamine) monograph synthesizing RxNorm 2604561, openFDA FAERS signals, and $9.90–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cold Flu (Acetaminophen, Dextromethorphan Hydrobromide) community threads and patient logs by age, biological sex, dosage, and treatment duration.